Ziconotide Acetate Drug Asset Due Diligence Report 2026

This Ziconotide Acetate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Ziconotide Acetate can convert its Synthetic peptide, Cyclic Peptide profile and Cav2.2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Ziconotide Acetate (query alias: ziconotide)
Modality / target	Synthetic peptide, Cyclic Peptide; Cav2.2; Cav2.2 blockers
Highest global status	Approved
Originator	Esteve Pharmaceuticals SA
Active developers	Esteve Pharmaceuticals SA, CPS Cito Pharma Services GmbH

The MCP disease footprint includes Chronic Pain, Pain. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03942848	Phase 3	Unknown status	44	Change in pain between both treatment arms assessed by the Visual Analogic Scale (VAS)
NCT04321408	Not Applicable	Recruiting	300	Describe the practical methods of using intrathecal treatments containing ziconotide: indication, initial intrathecal analgesic treatment and evolution of intrathecal analgesic treatment, efficacy and safety in the real clinical practice and monitoring.
NCT06541184	Not Applicable	Recruiting	85	Describe the characteristics of patients treated by intrathecal ziconotide for chronic non-cancer pain: demographic characteristics

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Real-Life Data on Ziconotide-Based Intrathecal Therapy in Patients With Cancer Pain: Interim Analysis of the Observational Practice in Clinics Registry

Not Applicable; n=211; evaluation: Positive. Reported fields: AE(After three months) = 62.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Ziconotide Acetate addresses Chronic Pain, Pain. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide, Cyclic Peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-01-13	TerSera Therapeutics Announces Closing of Divestiture of Infusion Specialty Therapies Business Unit to ESTEVE	Approved	Financial terms not disclosed
	Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt	Approved	US$80.0M stated total
2018-03-31	Riemser Pharma collaborates with Eisai to develop and market Prialt for non-opioid severe chronic pain in Europe.	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Ziconotide injection and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Method for preparing ziconotide by solid-liquid combination”. The milestone feed surfaced a patent-application signal described as “GLP-1 analogue and ziconotide composite slow-release microsphere preparation”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO